Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation

Twice-daily rivaroxaban after percutaneous left atrial appendage closure for atrial fibrillation

Background and aim: Rivaroxaban is an emerging oral anticoagulant for postoperative anticoagulation after percutaneous left atrial appendage closure (LAAC). Because a once-daily dosing regimen of rivaroxaban causes fluctuations in the drug plasma concentration, we studied the feasibility and safety...

Full description

Bibliographic Details
Main Authors: Yang-Qi Pan, Lu-Shen Jin, Sang Qian, Ting Jiang, Zhe-Ning Wang, Yi-Lian Chen, Yi-Xuan Qiu, Yi-Hao Wu, Jia-Yang Fu, Ling Li, Yuan-Nan Lin, Yue-Chun Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Pharmacology
Subjects:
rivaroxaban
left atrial appendage occlusion
atrial fibrillation
bleeding events
device-related thrombosis
stroke
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1344828/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1344828/full

Similar Items